10-K: MariMed Inc. Reports 10.9% Revenue Increase in 2023 Annual Filing

MariMed Inc. reports a 10.9% increase in total revenue for 2023, driven by growth in product sales, despite challenges in other revenue streams.

Summary

• MariMed Inc., a multi-state cannabis operator, reported a 10.9% increase in total revenue for the year ended December 31, 2023, reaching $148.6 million, compared to $134 million in 2022.
• The revenue growth was primarily driven by a 14.8% increase in product revenue, which includes both retail and wholesale sales, totaling $144.3 million in 2023.
• Wholesale revenue saw a significant jump of 48.4%, reaching $48.8 million, while retail sales increased by 2.9% to $95.5 million.
• Other revenue streams, including real estate rentals, supply procurement, management fees, and licensing fees, declined by 48.3% to $4.3 million.
• The company's cost of revenue increased by 18% to $82.7 million, resulting in a gross profit of $65.9 million, a 3.1% increase from the previous year.
• Operating expenses rose by 18.2% to $51.5 million, primarily due to increased personnel, marketing, and general and administrative costs.
• The company experienced a net loss of $16 million, primarily due to a $10.4 million loss on debt extinguishment and a $1.6 million other expense, which included a $0.7 million loss from a fraudulent payment.
• MariMed refinanced its debt with a $58.7 million secured credit facility, which allowed it to pay off previous loans and unencumber operating assets.
• The company operates 23 cannabis licenses across six states, with a focus on vertical integration and brand expansion.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue increased and the company secured a new credit facility, the net loss, increased operating expenses, and the fraudulent payment incident temper the positive aspects. The company is facing significant challenges and risks, but is also taking steps to grow and improve its operations.

Positives

• The company achieved significant growth in wholesale revenue, indicating strong market demand for its products.
• The new credit facility provides financial flexibility and reduces the cost of capital.
• MariMed is expanding its production capacity to meet the increasing demand for its branded products.
• The company is actively pursuing strategic acquisitions and new license applications to expand its footprint.
• The company has a strong portfolio of proprietary, premium brands that are award-winning and top sellers in multiple states.

Negatives

• The company experienced a net loss of $16 million, primarily due to a loss on debt extinguishment and a fraudulent payment.
• Other revenue streams, including real estate rentals, supply procurement, management fees, and licensing fees, declined significantly.
• Operating expenses increased due to higher personnel, marketing, and general and administrative costs.
• The company is subject to Section 280E of the Internal Revenue Code, which prohibits the deduction of certain ordinary business expenses.
• The company experienced a cybersecurity incident resulting in a $0.7 million loss from a fraudulent payment.

Risks

• Cannabis remains illegal under United States federal law, posing a significant risk to the company's operations.
• The company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements.
• The re-classification of cannabis or changes in United States controlled substance laws and regulations could have a material adverse effect on the business.
• The company faces increasing competition from other multi-state operators and single-state operators.
• The company may have difficulty accessing the service of banks, which may make it difficult to operate in certain markets.
• The company is subject to limits on its ability to own the licenses necessary to operate its business in certain states.
• The company is subject to potential risks related to, and arising from, acquiring companies or technologies.
• Cybersecurity incidents could disrupt operations and result in the compromise of proprietary and confidential information.
• The market price of the company's common stock has been historically volatile and could continue to be volatile.

Future Outlook

MariMed plans to continue executing its strategic growth plan, focusing on organic revenue growth, expanding into new markets, increasing brand revenue, and consolidating cannabis businesses. The company expects to complete the build-out of its cultivation facility in Mt. Vernon, Illinois in early 2024 and to commence adult-use sales in Delaware in late 2024.

Management Comments

• The company is focused on executing its strategic growth plan, with priority on activities that include completing the acquisition and consolidation of the client cannabis businesses.
• The company intends to increase revenue organically in states where it currently does business by developing additional assets and increasing product distribution.
• The company plans to expand its footprint into high-growth legal cannabis states through new license applications and/or acquisitions of existing cannabis businesses.
• The company aims to increase product brand revenue by introducing new, innovative products and expanding its award-winning brands.

Industry Context

The cannabis industry is rapidly evolving, with increasing competition and regulatory changes. MariMed's focus on vertical integration and brand development aligns with industry trends, but the company faces challenges related to federal illegality and varying state regulations. The company's ability to secure a lower-rate credit facility is a positive sign in a market where capital access can be difficult.

Comparison to Industry Standards

• MariMed's revenue growth of 10.9% is moderate compared to some other multi-state operators in the cannabis industry, which have seen higher growth rates due to aggressive expansion strategies.
• The company's focus on organic growth and brand development is similar to other successful MSOs, but its approach of acquiring and consolidating former clients is unique.
• The company's gross margin of 44.4% is within the range of industry averages, but its operating expenses are higher than some of its peers.
• The company's debt refinancing is a positive step, as many cannabis companies struggle with high interest rates and limited access to capital.
• Compared to companies like Curaleaf and Trulieve, which have significantly larger market caps and revenue, MariMed is a smaller player, but it is focused on building a sustainable business model.

Legal Proceedings

• The company settled a bankruptcy claim with the Plan Administrator of GenCanna Global Inc., reducing its unsecured general claim to $15.5 million.

Related Party Transactions

• The company leases its corporate offices from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the CRO.
• A subsidiary of the company paid distributions to the CEO, who owns a minority equity interest in such subsidiary.
• FSCC paid fees to a company partially owned by the CEO related to the initial formation, licensing and establishment of FSCC's cannabis operations.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the volatility of the company's stock price.
• Employees may be affected by the company's expansion and restructuring efforts.
• Customers may benefit from the company's expanded product offerings and improved retail experience.
• Suppliers may see increased demand for their products as the company expands its operations.
• Creditors may be reassured by the company's debt refinancing and improved financial stability.

Next Steps

• Complete the build-out of the cultivation facility in Mt. Vernon, Illinois.
• Commence adult-use sales in Delaware.
• Continue to expand production capacity in Massachusetts and Maryland.
• Pursue strategic acquisitions and new license applications.
• Continue to develop and launch new branded products.

Key Dates

Keywords

cannabis, multi-state operator, MSO, marijuana, cultivation, dispensary, wholesale, retail, licenses, brands, debt refinancing, acquisitions, product sales, financial results, regulation